CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will hold a conference call on Wednesday, September 12, 2007 at 8:30 a.m. Eastern Time to review the positive results of a quantitative analysis of the images from the Zemiva Phase 2b clinical trial using the company’s validated Normals reference database. The data were recently presented in an oral presentation at the American Society of Nuclear Cardiology (ASNC) conference and announced in a press release on Monday, September 10, 2007. Investors are invited to join Molecular Insight management and James E. Udelson, M.D., Associate Chief, Division of Cardiology and Director of Nuclear Cardiology at Tufts-New England Medical Center and lead investigator on the study, who will discuss the study’s outcomes and implications. The presentation will be followed by a question and answer session.
